US 12,251,383 B2
Methods and compositions for KRAS inhibitors
Alemayehu Gorfe Abebe, Houston, TX (US); Michael J. McCarthy, Houston, TX (US); Cynthia V. Pagba, Houston, TX (US); and Priyanka Prakash Srivastava, Houston, TX (US)
Filed by The Board of Regents of the University of Texas System, Austin, TX (US)
Filed on Sep. 8, 2021, as Appl. No. 17/469,457.
Application 17/469,457 is a division of application No. 16/449,785, filed on Jun. 24, 2019, granted, now 11,141,418, issued on Oct. 12, 2021.
Prior Publication US 2021/0401845 A1, Dec. 30, 2021
Int. Cl. A61K 31/519 (2006.01)
CPC A61K 31/519 (2013.01) 9 Claims
 
1. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound having a structure represented by a formula:

OG Complex Work Unit Chemistry
wherein R1 is C1-C6 alkyl;
wherein R2 is a C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
wherein R3 is C1-C8 alkyl; and
wherein R4 is, —(C1-C6 alkanediyl)—SF5, —(C1-C6 alkanediyl)—OH, —(C1-C6 alkanediyl)—SH, —(C1-C6 alkanediyl)—NH2, —(C1-C7 haloalkyl), —C1-C7 hydroxyalkyl, —(C1-C6 alkyl)(C═O) R5;
wherein R5 is hydroxy, amino, —O(C1-C6 alkyl), —O(C1-C6 haloalkyl), —NH(C1-C6 alkyl), or —N(C1-C6 alkyl)2, and a pharmaceutically acceptable carrier.